Aelis Farma
13
1
1
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
15.4%
2 terminated/withdrawn out of 13 trials
77.8%
-8.7% vs industry average
0%
0 trials in Phase 3/4
14%
1 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
Qualitative Effects of AEF0217 in Down Syndrome People
Role: lead
AEF0217 in Participants With Down Syndrome
Role: lead
Drug-Drug Interaction Between THC and AEF0117
Role: lead
The Effect of Food on the Oral Bioavailability of AEF0117 in Healthy Volunteers
Role: lead
Phase 1/2 Trial of AEF0217 in Participants With Down Syndrome
Role: lead
Effect of AEF0117 on Treatment-seeking Patients With Cannabis Use Disorder (CUD)
Role: lead
AEF0217 First-in-Human Phase I Study in 3 Parts (Single and Multiple Ascending Doses, and Food Effect) in Healthy Subjects.
Role: lead
Study of [4-14C] AEF0117 Following a Single Oral Dose in Healthy Male Subjects
Role: lead
Effect of AEF0117 on Subjective Effects of Cannabis in CUD Subjects
Role: lead
Assessment of Neural Oscillations in Adult Subjects With Down Syndrome and Typically Developing Subjects in Resting State and While Conducting Cognitive Tasks
Role: collaborator
Clinical Validation of the Bordeaux Maze Test
Role: collaborator
Multiple Ascending Dose to Study the Safety, Tolerability, PK and PD Effects of AEF0117
Role: lead
Single Ascending Dose to Study the Safety, Tolerability, PK and PD Effects of AEF0117
Role: lead
All 13 trials loaded